MINNEAPOLIS - (Business Wire) Medtronic, Inc. (NYSE: MDT) announced todayFrom PreciSense’s web page:
at its annual institutional investor and analyst meeting that the company
purchased substantially all glucose monitoring assets from PreciSense A/S, a
Denmark-based development company focused on continuous glucose monitoring (CGM)
technology. Specific terms of the acquisition were not disclosed.
“This strategic acquisition is an effort to expand Medtronic’s already
robust continuous glucose monitoring pipeline, and to develop a new CGM platform
to aid development of our ‘closed-loop’ system,” said Diabetes business unit
president and senior vice president at Medtronic, Chris O’Connell. “This
potentially disruptive technology could significantly broaden the use of CGM,
and help improve diabetes care for more patients.”
Non.invasive Glucose ReadingI am officially not holding my breath for non invasive (or semi non invasive since this sound like you invasively plant a microcapsule but read it non invasively) blood readings. Still this sounds like a promising line of pursuit and all the best to tem if they can be the first people to make some form of non invasive work.
The PreciSense System includes a microcapsule
placement unit and a light detecting non-invasive reader unit. The microcapsule
placement unit poses the right dose of glucose-responding microcapsules in the
upper layer of the skin, painlessly. The glucose assay components in the
microcapsules generate a fluorescence signal that corresponds to the glucose
level. The non-invasive reader unit monitors this glucose binding event through
FRET, Fluorescence Resonance Energy Transfer, which is directly related to the
concentration of glucose.